E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2007 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
12/18/07Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on January 23, 2008, to shareholders of record on January 9, 2008. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic te... 
Printer Friendly Version
11/26/07Quest Diagnostics to Speak at the Merrill Lynch Health Services Investor Conference
MADISON, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Merrill Lynch Health Services Investor Conference at the Merrill Lynch Headquarters in New York City on Tuesday, November 27, 2007. The Quest Diagnostics presentation is scheduled to begin at 10:15 a.m. Eastern Time. During the conference, the company will reiterate ... 
Printer Friendly Version
11/06/07Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
MADISON, N.J., Nov. 6 /PRNewswire-FirstCall/ -- The majority of people with diabetes and/or high blood pressure -- the two leading causes of chronic kidney disease (CKD) -- are not receiving recommended tests to identify this disease early, when medical treatment can slow or halt disease progression, according to the latest Quest Diagnostics Health Trends(TM) Report. In addition, the report's findings suggest that patients with early-stage CKD are not being well managed for contributin... 
Printer Friendly Version
11/01/07Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
First step for performing important diagnostics in physician offices MADISON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its HemoCue and Focus Diagnostics subsidiaries have received FDA 510(k) clearance for two new point of care tests. The HemoCue(R) White Blood Cell (WBC) Analyzer is a whole-blood test performed on finger-stick samples that a... 
Printer Friendly Version
10/26/07Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
-First national diagnostic testing company to license proprietary technology- MADISON, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it has entered into a non- exclusive license agreement for the heteroduplex tracking technology underlying Pathway Diagnostics' SensiTrop(TM) HIV co-receptor tropism test. Tropism refers to the way a virus targets host ... 
Printer Friendly Version
10/24/07Quest Diagnostics Reports Third Quarter Results
- Operating performance improvement continues - MADISON, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2007, income from continuing operations was $150 million, or $0.77 per diluted share, compared to $164 million, or $0.82 per diluted share in the third quarter of 2006. The third quarter of 2007 inc... 
Printer Friendly Version
10/09/07Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
Collaboration Expected to Drive Physician Adoption of Patient-Safety Technology eRx NOW(TM) Functionality Expanded to Include Quest Diagnostics Care360(TM) Physician Portal Lab Order and Results Capabilities LYNDHURST, N.J. and CHICAGO, Oct. 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services and a leading developer of healthcare IT... 
Printer Friendly Version
09/21/07Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
LYNDHURST, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 2007 UBS Global Life Sciences Conference in New York City on Monday, September 24, 2007. The Quest Diagnostics presentation is scheduled to begin at 4:30 p.m. Eastern Time. The presentation will be webcast live during the conference and will be available to regis... 
Printer Friendly Version
09/10/07Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
LYNDHURST, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bear Stearns Healthcare Conference in New York City on Tuesday, September 11, 2007. The Quest Diagnostics presentation is scheduled to begin at 9:30 a.m. Eastern Time. During the conference, the company will reiterate its 2007 guidance for revenues of between $... 
Printer Friendly Version
09/10/07Quest Diagnostics Again Selected as Part of Dow Jones Sustainability World and North American Indexes
LYNDHURST, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that it was again selected to be part of the Dow Jones Sustainability (DJSI) World and North American Indexes. The company was first added to the World Index in 2004 and the North American Index in 2005. According to DJSI, companies were identified as "sustainability leaders" and ranked accord... 
Printer Friendly Version
08/30/07Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
First commercial test available nationally LYNDHURST, N.J., Aug. 30 /PRNewswire-FirstCall/ -- A molecular diagnostic test that detects chromosome abnormalities associated with 85 developmental disorders affecting children now is commercially available from a national diagnostic testing company, affording testing and reimbursement by leading health plans across the U.S. Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, inf... 
Printer Friendly Version
08/17/07Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., Aug. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on October 17, 2007, to shareholders of record on October 3, 2007. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, informati... 
Printer Friendly Version
08/09/07Quest Diagnostics Drug Testing Index(R) Finds Cocaine Use at 10-Year Low Among U.S. Workers
Double-digit declines reported across the U.S.LYNDHURST, N.J., Aug 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- An unprecedented decline in cocaine use by American workers drove use of the illicit drug to a new low during the first half of 2007, according to the "Quest Diagnostics Drug Testing Index: Cocaine Use Among America's Workers -- A Special 2007 Mid-Year Report." Released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic ... 
Printer Friendly Version
07/24/07Quest Diagnostics Reports Second Quarter 2007 Results
LYNDHURST, N.J., July 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2007, income from continuing operations was $142 million, or $0.73 per diluted share, compared to $156 million, or $0.78 per diluted share, in the second quarter of 2006. The second quarter of 2007 includes the results of AmeriPath, Inc., which was acquired on Ma... 
Printer Friendly Version
07/19/07Quest Diagnostics Announces New Testing Technique for Improved Diagnosis of Metabolic And Nutritional Disorders
LYNDHURST, N.J., July 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced a new, proprietary diagnostic testing technique to help physicians diagnose genetic metabolic disorders, such as phenylketonuria (PKU) and homocystinuria. Genetic metabolic disorders can impair a child's mental and physical development. The new technique measures amino acids in blood plasma, urine ... 
Printer Friendly Version
07/17/07Quest Diagnostics Launches National Patient Appointment Scheduling
Industry's first national scheduling system provides convenient scheduling options and reduced wait times for patients LYNDHURST, N.J., July 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced the first national patient appointment-scheduling system in the diagnostic testing service industry. The new system gives patients the option to schedule appointm... 
Printer Friendly Version
06/23/07Diabetes Patients Make Significant Gains in Disease Control; Still, Nearly Half Fail to Reach ADA Treatment Goals
Gains come soon after diagnosis then plateau; young male adults fare worse than females Test results found to worsen in winter Six-year data released from nation's largest laboratory testing database CHICAGO, June 23 /PRNewswire/ -- Over the last six years, Americans being treated for diabetes improved control of their disease by a significant 44.4 percent. As of December, 2006, more than half (54.6 percent) had reached ... 
Printer Friendly Version
06/22/07Quest Diagnostics to Speak at the Jefferies Healthcare Conference
LYNDHURST, N.J., June 22 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies Healthcare Conference on Tuesday, June 26, 2007. The Quest Diagnostics presentation is scheduled to begin at 9:50 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following... 
Printer Friendly Version
06/20/07Quest Diagnostics Announces Pricing of Senior Notes
LYNDHURST, N.J., June 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information, and services, announced today that it priced $800 million in aggregate principal amount of senior notes in a public offering. The notes were sold in two tranches, as follows: $375 million of 6.40% senior notes due 2017 and $425 million of 6.95% senior notes due 2037. The offering is expected to close on June 22, 2007. The net p... 
Printer Friendly Version
06/19/07Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
LYNDHURST, N.J., June 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information, and services, announced today that it intends to offer $800,000,000 in aggregate principal amount in two series of senior notes, in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and unconditionally gu... 
Printer Friendly Version
06/19/07Quest Diagnostics Incorporated Announces Completion of Tender Offer for the 10 1/2% Senior Subordinated Notes Due 2013 of AmeriPath, Inc.
LYNDHURST, N.J., June 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostics testing, information and services, announced today that it has completed its cash tender offer for the outstanding $350 million, 10 1/2% Senior Subordinated Notes due 2013 (the "Notes") (CUSIP Nos. 03071D AC 3 and 03071D AA 7) of AmeriPath, Inc. ("AmeriPath"). The cash tender offer expired, as scheduled, on June 18, 2007, at 12:00 midnight, ET, (t... 
Printer Friendly Version
06/07/07Quest Diagnostics Extends Agreement With CIGNA Healthcare
LYNDHURST, N.J., June 7 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it has signed a multi-year contract extension with CIGNA HealthCare and will remain a participating provider in all markets for all products. Quest Diagnostics is the largest provider of laboratory services to CIGNA HealthCare, providing its members and providers with the nation's broadest acces... 
Printer Friendly Version
06/05/07Quest Diagnostics Incorporated Announces Pricing and Receipt of Requisite Consents for Cash Tender Offer and Consent Solicitation for the 10 1/2% Senior Subordinated Notes Due 2013 of AmeriPath, Inc.
LYNDHURST, N.J., June 5 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostics testing, information and services, announced today the determination of pricing in connection with its cash tender offer and consent solicitation for any and all of the outstanding $350,000,000 principal amount 10 1/2% Senior Subordinated Notes due 2013 (the "Notes") (CUSIP Nos. 03071D AC 3 and 03071D AA 7) of AmeriPath, Inc. ("AmeriPath"). The... 
Printer Friendly Version
05/31/07Quest Diagnostics Completes Acquisition of AmeriPath
LYNDHURST, N.J., MAY 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced that today it completed its previously announced acquisition of AmeriPath, Inc., a national diagnostic testing company. "This acquisition creates the world's premier cancer diagnostics company focused on dermatopathology, anatomic pathology and molecular diagnostics," said Surya N. Mohapa... 
Printer Friendly Version
05/30/07Quest Diagnostics Plans to Complete Acquisition of AmeriPath on May 31
LYNDHURST, N.J., May 30 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today that it plans to complete its previously announced acquisition of AmeriPath, Inc. on May 31, 2007. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on May 29, 2007. About AmeriPath AmeriPath, a leading national provider of physician-based anatomic pathology, derm... 
Printer Friendly Version
05/29/07Quest Diagnostics to Speak at the Bank of America Healthcare Conference 2007
LYNDHURST, N.J., May 29 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America Healthcare Conference on Thursday, May 31, 2007, at the Four Seasons Hotel in Las Vegas, Nevada. The Quest Diagnostics presentation is scheduled to begin at 5:40 p.m. Eastern Time. During the conference, the company will reiterate its 2007 guidance f... 
Printer Friendly Version
05/21/07Study Reports Point-of-Care Test to be as Accurate as Conventional Laboratory Analysis in Detecting Kidney Disease in Patients with Diabetes and Cardiovascular Disease
CHICAGO, May 21 /PRNewswire-FirstCall/ -- A study presented today at the American Society of Hypertension, Inc. (ASH) Twenty-Second Annual Scientific Meeting and Exposition (ASH 2007) in Chicago reports that the HemoCue Albumin 201 system, a point-of-care diagnostic test developed by HemoCue AB, can detect microalbuminuria, a biological marker for kidney and cardiovascular disease as accurately as conventional laboratory tests. HemoCue, a Quest Diagnostics (NYSE: DGX) company, is the d... 
Printer Friendly Version
05/21/07Quest Diagnostics Commences Cash Tender Offer for AmeriPath 10 1/2% Senior Subordinated Notes Due 2013
LYNDHURST, N.J., May 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostics testing, information and services, announced today that it has commenced a cash tender offer for all of the outstanding $350,000,000 principal amount 10 1/2% Senior Subordinated Notes due 2013 (CUSIP Nos. 03071D AC 3 and 03071D AA 7) of AmeriPath, Inc. (AmeriPath). The tender offer is being made by Quest Diagnostics in connection with its previousl... 
Printer Friendly Version
05/10/07Award for 'Best Employer for Healthy Lifestyles' Given to Quest Diagnostics
HealthyQuest Employee Wellness Program Features Unique Combination of Diagnostic Screening, Lifestyle Assessment and Health Education LYNDHURST, N.J., May 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today that the National Business Group on Health, an association of 266 large U.S. employers, has awarded its 2007 Best Employers for Healthy Lifestyles Gold Award to the... 
Printer Friendly Version
05/08/07Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., May 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on July 18, 2007, to shareholders of record on July 5, 2007. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information and se... 
Printer Friendly Version
04/19/07Quest Diagnostics Reports First Quarter 2007 Results
LYNDHURST, N.J., April 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2007, income from continuing operations was $108 million, or $0.55 per diluted share compared to $155 million, or $0.77 per diluted share in the first quarter of 2006. Earnings in the first quarter were reduced by an estimated $0.17 per share as a result of... 
Printer Friendly Version
04/17/07Quest Diagnostics' MedPlus(R) Subsidiary Selected To Develop The Lab Information System For The Province of British Columbia's Electronic Health Record System
One of North America's largest electronic health networks will deliver better care at lower costLYNDHURST, N.J., April 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that its healthcare information technology subsidiary MedPlus, Inc., has been selected as a subcontractor by Sun Microsystems (B.C.) Inc., a subsidiary of Sun Microsystems of Canada Inc., and subcontractors to develop and implement a comprehensive electronic ... 
Printer Friendly Version
04/16/07Quest Diagnostics to Acquire AmeriPath in a Transaction Valued at $2 Billion
-- Establishes Leading Position in Cancer Diagnostics with a Focus on Dermatopathology, Anatomic Pathology and Molecular Diagnostics -- -- Strengthens Leadership in Hospital and Esoteric Testing -- -- Enhances Position as World's Premier Diagnostic Testing Company -- LYNDHURST, N.J. and PALM BEACH GARDENS, Fla., April 16 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and service... 
Printer Friendly Version
03/22/07Quest Diagnostics Selected as Sole Laboratory Service Provider to National Health Service Hospital and Primary Care Trust
Agreement strengthens company's U.K. presence LYNDHURST, N.J., March 22 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading U.S. provider of diagnostic testing, information and services, announced today that it has been awarded a new, five-year contract with the U.K.'s National Health Service West Middlesex University Hospital Trust and the Hounslow Primary Care Trust of London to provide end-to-end diagnostic testing and related support se... 
Printer Friendly Version
03/15/07Quest Diagnostics to Speak at the Lehman Brothers Tenth Annual Healthcare Conference
LYNDHURST, N.J., March 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lehman Brothers Tenth Annual Healthcare Conference on Monday, March 19, 2007, at the Loews Miami Beach Hotel in Miami, Florida. The Quest Diagnostics presentation is scheduled to begin at 4:15 p.m. Eastern Time. The presentation will be webcast live during the con... 
Printer Friendly Version
03/07/07Drug Use Hits New Low Among U.S. Workers in 2006, According to Quest Diagnostics' Drug Testing Index(R)
-- Lowest levels since 1988 -- -- Significant decline in use of amphetamines and marijuana continues trend from previous year -- LYNDHURST, N.J., March 7 /PRNewswire-FirstCall/ -- A continued decline in drug positivity for the amphetamine class of drugs among safety-sensitive workers, coupled with a decrease in positive marijuana drug test results among the general U.S. workforce, drove workplace drug use to a new low in 2006. The... 
Printer Friendly Version
03/05/07Focus Diagnostics Receives FDA Clearance to Market Plexus HerpeSelect
Focus Diagnostics Receives FDA Clearance to Market Plexus HerpeSelect Monday March 5, 6:30 pm ET CYPRESS, Calif., March 5 /PRNewswire-FirstCall/ -- Focus Diagnostics, Inc., a wholly owned subsidiary of Quest Diagnostics Incorporated, (NYSE: DGX - News), today announced it has received FDA 510k clearance to market its new Plexus(TM) HerpeSelect® 1 and 2 IgG test kit, the first multiplex type- specific HSV serology panel using xMAP® technology from Luminex Corporation. Focus Diagnostics... 
Printer Friendly Version
02/22/07MedPlus' ChartMaxx(R) Earns Top Ranking in the '2006 Top 20 Year-End Best in KLAS' Report for Third Consecutive Year
LYNDHURST, N.J., Feb. 22 /PRNewswire-FirstCall/ -- MedPlus' ChartMaxx(R), an enterprise-wide electronic health record solution for hospitals, Integrated Delivery Networks and healthcare communities, placed first in Document Management and Imaging (DMI) in the "2006 Top 20: Year-End Best in KLAS" report issued by KLAS Enterprises. ((C) 2006 KLAS Enterprises, LLC. All rights reserved). This marks the third consecutive year and fourth time in five years that ChartMaxx has placed first in... 
Printer Friendly Version
02/14/07National Survey Shows Physicians Have Clear Preference Between the Two Largest Diagnostic Laboratories
- Results show overwhelming preference for Quest Diagnostics - LYNDHURST, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today results of a national physician study on preference and performance of medical laboratory services. When physicians were asked which of the two largest national laboratories they preferred, the majority of physicians expressed a preferenc... 
Printer Friendly Version
02/13/07Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on April 18, 2007, to shareholders of record on April 4, 2007. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information an... 
Printer Friendly Version
02/01/07Quest Diagnostics Acquires HemoCue for Approximately $420 Million, Entering Market for Near Patient Testing
LYNDHURST, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading U.S. provider of diagnostic testing, information and services, announced today that it has acquired HemoCue, a Swedish company specializing in near patient testing, also known as point-of- care testing, from the private equity firm EQT II B.V. in a cash transaction valued at approximately $420 million. The acquisition will allow Quest Diagnostics to enter the growing near patient t... 
Printer Friendly Version
01/29/07Quest Diagnostics to Speak at Wachovia Securities 2007 Healthcare Conference
LYNDHURST, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Wachovia Securities 2007 Healthcare Conference on Tuesday, January 30, 2007, at the Langham Hotel, Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 8:30 a.m. Eastern Time. The presentation will be webcast live during the conferenc... 
Printer Friendly Version
01/25/07Quest Diagnostics Reports Strong Results for Fourth Quarter and Full Year 2006
- Company provides 2007 guidance - LYNDHURST, N.J., Jan. 25 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2006, income from continuing operations was $151 million, or $0.77 per diluted share compared to $149 million, or $0.73 per diluted share for the prior year. Fourth quarter revenues from continuing... 
Printer Friendly Version
01/19/07Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology to Screen for Most Common Inherited Mental Impairment, Fragile X Syndrome
New Technology Will Allow for Widespread Population-Based Carrier Screenings LYNDHURST, N.J., Jan. 19 /PRNewswire-FirstCall/ -- In a move that promises to advance physicians' ability to widely screen for Fragile X Syndrome (FXS), the most common form of inherited mental retardation,(1) Quest Diagnostics Incorporated (NYSE: DGX) today announced the signing of a worldwide license agreement with U.S. Genomics. The terms grant Quest Diagnostics rights to develop an advanced screening meth... 
Printer Friendly Version
01/09/07Quest Diagnostics to Speak at the 25th Annual JPMorgan Healthcare Conference
LYNDHURST, N.J., Jan 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 25th Annual JPMorgan Healthcare Conference on Wednesday, January 10, 2007, at the Westin St. Francis in San Francisco, California. The Quest Diagnostics presentation is scheduled to begin at 12:30 p.m. Eastern Time. The presentation will be web... 
Printer Friendly Version